Zepbound® providers &
prescriptions in Greenville, NC
Verified Zepbound providers in Greenville, NC. Checked against the NPI registry, never ranked by who pays us.[7]
Find a Zepbound provider in North Carolina.
Every entry is checked against the federal NPI registry. We do not accept payment for placement.
How to get Zepbound in Greenville.
35 GLP-1 prescribers and 7 local resource types are on record for Greenville, plus 3 nearby towns in the directory.
Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm North Carolina’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.
An injectable medication for chronic weight management in adults. Same molecule as Mounjaro.
Zepbound is the brand name Eli Lilly uses for tirzepatide approved for chronic weight management. It is a once-weekly subcutaneous injection and the first approved dual GIP/GLP-1 receptor agonist. The identical molecule, marketed as Mounjaro, is the FDA-approved formulation for type 2 diabetes.[2][3]
In SURMOUNT-1, adults with obesity (without diabetes) lost a mean of 20.9% of body weight on the 15 mg dose at 72 weeks, versus 3.1% with placebo. That is among the largest average weight reductions reported for an anti-obesity medication. Zepbound is approved as an adjunct to a reduced-calorie diet and increased physical activity.[1]
Community health · CDC
Weight & metabolic health in Greenville
Greenville, North Carolina has a population of 87,521 people. The adult obesity rate in Greenville is an age-adjusted estimate of 41.3%, 6.8 percentage points above the North Carolina state rate of 34.5%. Diagnosed diabetes reaches 12.5% of adults in Greenville. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 26% of adults in Greenville.
- of Greenville adults have obesity
- 41.3%
- diagnosed diabetes
- 12.5%
- no regular physical activity
- 26%
Age-adjusted estimates for Greenville, community figures, not individual risk. CDC PLACES, 2025 release.
The prescription is one part. Here is the rest, in Greenville.
Trials of tirzepatide paired the drug with diet counseling and regular activity. Every name below is a real listing near Greenville, NC, ordered as the registry lists them, never by who pays us.
Gyms near you
A gym gives you the regular movement that keeps muscle while the weight comes off.
1913 E Fire Tower Rd Ste e
Registered dietitians
A registered dietitian builds the food plan around your prescription. Call to ask about GLP-1 nutrition plans and insurance.
105 Wesley Rd
2100 Stantonsburg Rd
What the trials actually showed.
We summarize the SURMOUNT weight-management program. Figures are means at the 72-week primary endpoint, by dose.
Most side effects are gastrointestinal and resolve within weeks.
The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]
Most directories hide the price. We don't.
Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.
Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.
NPI-verified Zepbound (tirzepatide) prescribers and clinics, never ranked by who pays us.
Find NPI-verified Zepbound (tirzepatide) doctors, clinics, and pharmacies in the states we cover, never ranked by who pays us.
The questions people ask before they book.
Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.
Zepbound and Mounjaro are both tirzepatide, made by Eli Lilly, but they carry different FDA-approved indications. Zepbound is approved for chronic weight management; Mounjaro is approved for type 2 diabetes. Insurers treat them as separate products, and weight-loss coverage is far more restricted than diabetes coverage.[1]